Peptide Comparison
Tesamorelin vs Hulk Stack
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Tesamorelin has stronger documented evidence (FDA-Approved) than Hulk Stack (Anecdotal) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Tesamorelin | Hulk Stack | |
|---|---|---|
| Class | GHRH analog (FDA-approved) | GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion | Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. |
| Route | SC injection | SC injection (typically 2-3 separate sites) |
| Half-life | ~26 min | CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs |
| Dosage (research) | 2 mg SC daily (FDA label) | Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks |
| Evidence tier | FDA-Approved | Anecdotal |
| Research depth | 127 indexed | — |
| Availability | Prescription | Compounding Restricted |
| Reported risks | Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 | Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Tesamorelin or Hulk Stack?
Tesamorelin has stronger documented evidence (FDA-Approved) than Hulk Stack (Anecdotal) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Hulk Stack may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Tesamorelin and Hulk Stack?
Tesamorelin is classed as GHRH analog (FDA-approved); Hulk Stack is classed as GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog. Reported mechanism: Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion; Hulk Stack, Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. Reported half-life: Tesamorelin, ~26 min; Hulk Stack, CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs. Routes in published studies: Tesamorelin, SC injection; Hulk Stack, SC injection (typically 2-3 separate sites).
Which has stronger evidence, Tesamorelin or Hulk Stack?
Tesamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tesamorelin is graded FDA-Approved, with 13 cited sources on its reference page and 127 indexed studies. Hulk Stack is graded Anecdotal, with 3 cited sources on its reference page.
Which is more accessible, Tesamorelin or Hulk Stack?
Tesamorelin is FDA-approved and Hulk Stack is not. Catalog status: Tesamorelin, Prescription; Hulk Stack, Compounding Restricted.
Are Tesamorelin and Hulk Stack ever combined?
Tesamorelin and Hulk Stack appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…